Cited 0 times in
LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.